Abstract

Research Article

Research Progress of BTG2 as a Tumor Prognostic Factor

Wanting Yang, Peizheng Yang, Yan Li, Yinfeng Yang* and Jinghui Wang*

Published: 21 June, 2023 | Volume 7 - Issue 1 | Pages: 014-017

Cancer is a major public health issue and the main cause of death worldwide. Despite improvements in diagnostic techniques and treatment methods, cancer still seriously affects the quality of life of patients, which cause serious social and economic burdens. Therefore, there is an urgent need to identify potential biomarkers to improve diagnosis, treatment, and prognosis of cancer. BTG2 is a cell proliferation suppressor gene that serves as a tumor suppressor gene in the occurrence and development of various tumors. Many studies have shown that BTG2 can serve as a prognostic marker in various tumors. So, fully tap the potentials of BTG2 as a tumor prognostic marker will bring more possibilities to provide a new method or new diagnostic and therapeutic tool for treating cancer.

Read Full Article HTML DOI: 10.29328/journal.acst.1001036 Cite this Article Read Full Article PDF

References

  1. Mao B, Zhang Z, Wang G. BTG2: a rising star of tumor suppressors (review). Int J Oncol. 2015 Feb;46(2):459-64. doi: 10.3892/ijo.2014.2765. Epub 2014 Nov 18. PMID: 25405282.
  2. Winkler GS. The mammalian anti-proliferative BTG/Tob protein family. J Cell Physiol. 2010 Jan;222(1):66-72. doi: 10.1002/jcp.21919. PMID: 19746446.
  3. Matsuda S, Rouault J, Magaud J, Berthet C. In search of a function for the TIS21/PC3/BTG1/TOB family. FEBS Lett. 2001 May 25;497(2-3):67-72. doi: 10.1016/s0014-5793(01)02436-x. PMID: 11377414.
  4. Kim SH, Jung IR, Hwang SS. Emerging role of anti-proliferative protein BTG1 and BTG2. BMB Rep. 2022 Aug;55(8):380-388. doi: 10.5483/BMBRep.2022.55.8.092. PMID: 35880434; PMCID: PMC9442347.
  5. Duriez C, Moyret-Lalle C, Falette N, El-Ghissassi F, Puisieux A. BTG2, its family and its tutor. Bull Cancer. 2004 Jul-Aug;91(7-8):E242-53. PMID: 15381462.
  6. Zhou L, Liang X, Zhang L, Yang L, Nagao N, Wu H, Liu C, Lin S, Cai G, Liu J. MiR-27a-3p functions as an oncogene in gastric cancer by targeting BTG2. Oncotarget. 2016 Aug 9;7(32):51943-51954. doi: 10.18632/oncotarget.10460. PMID: 27409164; PMCID: PMC5239526.
  7. Huang CS, Zhai JM, Zhu XX, Cai JP, Chen W, Li JH, Yin XY. BTG2 Is Down-Regulated and Inhibits Cancer Stem Cell-Like Features of Side Population Cells in Hepatocellular Carcinoma. Dig Dis Sci. 2017 Dec;62(12):3501-3510. doi: 10.1007/s10620-017-4829-y. Epub 2017 Nov 2. PMID: 29098552.
  8. Shen S, Zhang R, Guo Y, Loehrer E, Wei Y, Zhu Y, Yuan Q, Moran S, Fleischer T, Bjaanaes MM, Karlsson A, Planck M, Staaf J, Helland Å, Esteller M, Su L, Chen F, Christiani DC. A multi-omic study reveals BTG2 as a reliable prognostic marker for early-stage non-small cell lung cancer. Mol Oncol. 2018 Jun;12(6):913-924. doi: 10.1002/1878-0261.12204. Epub 2018 May 4. PMID: 29656435; PMCID: PMC5983115.
  9. Zhang SJ, Ma J, Wu JC, Hao ZZ, Zhang YA, Zhang YJ. Circular RNA circCRIM1 suppresses lung adenocarcinoma cell migration, invasion, EMT, and glycolysis through regulating miR-125b-5p/BTG2 axis. Eur Rev Med Pharmacol Sci. 2021 May;25(9):3399. doi: 10.26355/eurrev_202105_25807. PMID: 34002808.
  10. Zhang XZ, Chen MJ, Fan PM, Jiang W, Liang SX. BTG2Serves as a Potential Prognostic Marker and Correlates with Immune Infiltration in Lung Adenocarcinoma. Int J Gen Med. 2022 Mar 8;15:2727-2745. doi: 10.2147/IJGM.S340565. PMID: 35300128; PMCID: PMC8922043.
  11. Jiang H, Zhu Y, Zhou Z, Xu J, Jin S, Xu K, Zhang H, Sun Q, Wang J, Xu J. PRMT5 promotes cell proliferation by inhibiting BTG2 expression via the ERK signaling pathway in hepatocellular carcinoma. Cancer Med. 2018 Mar;7(3):869-882. doi: 10.1002/cam4.1360. Epub 2018 Feb 14. PMID: 29441724; PMCID: PMC5852340.
  12. Lv X, Yu H, Zhang Q, Huang Q, Hong X, Yu T, Lan H, Mei C, Zhang W, Luo H, Pang P, Shan H. SRXN1 stimulates hepatocellular carcinoma tumorigenesis and metastasis through modulating ROS/p65/BTG2 signalling. J Cell Mol Med. 2020 Sep;24(18):10714-10729. doi: 10.1111/jcmm.15693. Epub 2020 Aug 3. PMID: 32746503; PMCID: PMC7521256.
  13. Huang CS, Zhai JM, Zhu XX, Cai JP, Chen W, Li JH, Yin XY. BTG2 Is Down-Regulated and Inhibits Cancer Stem Cell-Like Features of Side Population Cells in Hepatocellular Carcinoma. Dig Dis Sci. 2017 Dec;62(12):3501-3510. doi: 10.1007/s10620-017-4829-y. Epub 2017 Nov 2. PMID: 29098552.
  14. Powell E, Shao J, Yuan Y, Chen HC, Cai S, Echeverria GV, Mistry N, Decker KF, Schlosberg C, Do KA, Edwards JR, Liang H, Piwnica-Worms D, Piwnica-Worms H. p53 deficiency linked to B cell translocation gene 2 (BTG2) loss enhances metastatic potential by promoting tumor growth in primary and metastatic sites in patient-derived xenograft (PDX) models of triple-negative breast cancer. Breast Cancer Res. 2016 Jan 27;18(1):13. doi: 10.1186/s13058-016-0673-9. PMID: 26818199; PMCID: PMC4728775.
  15. Sundaramoorthy S, Devanand P, Ryu MS, Song KY, Noh DY, Lim IK. TIS21/BTG2inhibits breast cancer growth and progression by differential regulation of mTORc1 and mTORc2-AKT1-NFAT1-PHLPP2 signaling axis. J Cancer Res Clin Oncol. 2018 Aug;144(8):1445-1462. doi: 10.1007/s00432-018-2677-6. Epub 2018 May 28. PMID: 29808317.
  16. Zhu C, Zhang S, Xue A, Feng G, Fan S. Elevated BTG2 improves the radiosensitivity of non-small cell lung cancer (NSCLC) through apoptosis. Thorac Cancer. 2022 May;13(10):1441-1448. doi: 10.1111/1759-7714.14410. Epub 2022 Apr 7. PMID: 35388633; PMCID: PMC9108063.
  17. Chen Z, Chen X, Lu B, Gu Y, Chen Q, Lei T, Nie F, Gu J, Huang J, Wei C, Sun M, Wang Z. Up-regulated LINC01234 promotes non-small-cell lung cancer cell metastasis by activating VAV3 and repressing BTG2 expression. J Hematol Oncol. 2020 Jan 20;13(1):7. doi: 10.1186/s13045-019-0842-2. PMID: 31959200; PMCID: PMC6972004.
  18. Shen S, Zhang R, Guo Y, Loehrer E, Wei Y, Zhu Y, Yuan Q, Moran S, Fleischer T, Bjaanaes MM, Karlsson A, Planck M, Staaf J, Helland Å, Esteller M, Su L, Chen F, Christiani DC. A multi-omic study reveals BTG2 as a reliable prognostic marker for early-stage non-small cell lung cancer. Mol Oncol. 2018 Jun;12(6):913-924. doi: 10.1002/1878-0261.12204. Epub 2018 May 4. PMID: 29656435; PMCID: PMC5983115.
  19. Yuniati L, Scheijen B, van der Meer LT, van Leeuwen FN. Tumor suppressors BTG1 and BTG2: Beyond growth control. J Cell Physiol. 2019 May;234(5):5379-5389. doi: 10.1002/jcp.27407. Epub 2018 Oct 23. PMID: 30350856; PMCID: PMC6587536.
  20. Guo D, Hong L, Ji H, Jiang Y, Lu L, Wang X, Huang H. The Mutation of BTG2Gene Predicts a Poor Outcome in Primary Testicular Diffuse Large B-Cell Lymphoma. J Inflamm Res. 2022 Mar 10;15:1757-1769. doi: 10.2147/JIR.S341355. PMID: 35300216; PMCID: PMC8923029.
  21. Wang W, Guo H, Zhou S, Zhu J, Liu Y, Yu R, Pu J. Expression and clinical significance of B cell translocation gene 2 in esophageal squamous cell carcinoma. Int J Clin Exp Pathol. 2021 Apr 15;14(4):475-483. PMID: 33936370; PMCID: PMC8085815.
  22. Erfani M, Zamani M, Tamaddon G, Hosseini SV, Mokarram P. Expression and methylation status of BTG2PPP1CA, and PEG3genes in colon adenocarcinoma cell lines: promising treatment targets. Gastroenterol Hepatol Bed Bench. 2022;15(4):395-405. doi: 10.22037/ghfbb.v15i4.2577. PMID: 36762213; PMCID: PMC9876769.
  23. Wang J, Li H, Wang L, Zhang J, Li M, Qiao L, Zhang J, Liu L, Zhang C, Gao J, Li W. Transcriptomic Analyses Reveal B-Cell Translocation Gene 2 as a Potential Therapeutic Target in Ovarian Cancer. Front Oncol. 2021 Aug 17;11:681250. doi: 10.3389/fonc.2021.681250. PMID: 34485119; PMCID: PMC8415965.
  24. Gao SS, Yang XH, Wang M. Inhibitory effects of B‑cell translocation gene 2 on skin cancer cells via the Wnt/β‑catenin signaling pathway. Mol Med Rep. 2016 Oct;14(4):3464-8. doi: 10.3892/mmr.2016.5596. Epub 2016 Aug 8. PMID: 27510158.
  25. Ficazzola MA, Fraiman M, Gitlin J, Woo K, Melamed J, Rubin MA, Walden PD. Antiproliferative B cell translocation gene 2 protein is down-regulated post-transcriptionally as an early event in prostate carcinogenesis. Carcinogenesis. 2001 Aug;22(8):1271-9. doi: 10.1093/carcin/22.8.1271. PMID: 11470758.
  26. Zhao LM, Pang AX. Iodine-131 treatment of thyroid cancer cells leads to suppression of cell proliferation followed by induction of cell apoptosis and cell cycle arrest by regulation of B-cell translocation gene 2-mediated JNK/NF-κB pathways. Braz J Med Biol Res. 2017 Jan 16;50(1):e5933. doi: 10.1590/1414-431X20165933. PMID: 28099584; PMCID: PMC5264532.
  27. Zhang L, Huang H, Wu K, Wang M, Wu B. Impact of BTG2 expression on proliferation and invasion of gastric cancer cells in vitro. Mol Biol Rep. 2010 Jul;37(6):2579-86. doi: 10.1007/s11033-009-9777-y. Epub 2009 Sep 2. PMID: 19728149.

Figures:

Similar Articles

Recently Viewed

Read More

Most Viewed

Read More

Help ?